Beihai Biotechnology's third-generation taxane derivative new drug was approved for clinical use

Text|Pharmaceutical Mission Hills

According to the announcement of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, the 2.

Screenshot source: CDE official website

Beihai Biotechnology is a biomedical company in the clinical stage, committed to developing innovative tumor drugs that are patient-centric and have unmet clinical needs

According to the press release of Beihai Biotechnology, cabazitaxel is a second-generation taxane anti-tumor drug, which was first developed by Sanofi and has not yet been listed in China

This time in China, the clinical research indication for BH002 injection approved is "for the treatment of metastatic castration-resistant prostate cancer receiving docetaxel treatment"

Prostate cancer is a high incidence of malignant tumors in men.

According to the press release of Beihai Biotechnology, cabazitaxel has a significant therapeutic effect on mCRPC

Reference materials:

[1] Drug Evaluation Center of China National Medical Products Administration.